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ABSTRACT 
Purpose Adiponectin gene variations have been associated with obesity. There are few 
interventional studies analyzing this association. The aim of this study was to analyze 
the effects of a nutritional intervention with Mediterranean-style diet and three  
(-4034A/C, +45T/G and +276 G/T) adiponectin gene variants on 3-year body weight 
changes in high cardiovascular risk patients 
Subjects and methods A total of 737 participants, aged 55-80 at high cardiovascular 
risk were assigned to a low-fat diet or to a Mediterranean-style diet (MD) groups, one 
with high intake of virgin olive oil (VOO) and the other with high intake of nuts. 
Anthropometric parameters were taken at baseline and after 3-year follow-up, and the 
genotyping of the -4034A/C, +45T/G and +276 G/T polymorphisms was done. 
Results GG genotype of the +45T/G polymorphism was associated with 3-year higher 
body weight gain (B=1.399; B=0.043). TT genotype of the +276G/T polymorphism was 
linked to the highest 3-year body weight gain in men. Both Mediterranean diets 
appeared to reverse this effect (p for interaction=0.053). 
Conclusion Adiponectin gene variation appeared to be associated with 3-year body 
weight changes in a high cardiovascular risk population. This association may be 
modulated by a nutritional intervention with a Mediterranean-style diet. 
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INTRODUCTION 
Adipose tissue, traditionally considered as an energy storage depot, has demonstrated to 
be an active endocrine organ secreting numerous proteins that play important metabolic 
roles [1]. Adiponectin is abundantly expressed in adipose tissue [2], and can have 
antiatherogenic, antiinflammatory, and insulin-sensitizing properties [3]. Low-plasma 
adiponectin levels have been observed in patients with obesity [4-6], coronary artery 
disease [7-9] and type 2 diabetes [10].  
A synonymous SNP in exon 2 (45T/G) has been significantly associated with obesity 
and metabolic syndrome as an independent SNP [11], or as a haplotype when combined 
with 276G/T, located in intron 2 [12]. Likewise the promoter region gene variants have 
been implicated in obesity and type 2 diabetes features [13, 14].  
Moreover, modifiable factors, such as diet, which could induce increases in adiponectin, 
might be useful for improving the outcomes of such disease. Since the Mediterranean 
diet was first defined by Keys and Grande [15], it has been postulated as beneficial 
against obesity [16] and cardiovascular disease [16, 18]. Olive oil consumption, which 
was the main source of dietary lipids (monounsaturated fatty acids) in traditional 
Mediterranean diets, has been widely related with this protective effect [18-21]. Also, 
tree nuts (a good source of polyunsaturated fatty acids) are an integral part of the 
Mediterranean food pattern and previous studies have found nut consumption to be 
associated with reduced risk of cardiovascular disease [22-24]. In this context the 
PREDIMED project is a clinical trial aimed at assessing the effects of the 
Mediterranean diet on the primary prevention of cardiovascular disease 
(http://www.predimed.org).  
We hypothesized that a Mediterranean-style diet might be able to outweigh the tendency 
to higher weight gain associated with these variants of the adiponectin gene. 
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The aim of this study was to analyze the effects of a nutritional intervention with a 
Mediterranean-style diet and three (-4034A/C, +45T/G and +276 G/T) adiponectin gene 
variants on 3-year body weight changes in high cardiovascular risk patients. 
 
MATERIAL AND METHODS 
Study population 
The present study has been conducted within the frame of the PREDIMED project. The 
PREDIMED project is a clinical trial aimed at assessing the effects of the 
Mediterranean diet on the primary prevention of cardiovascular disease 
(http://www.predimed.org). It could be thought that there is already enough available 
evidence to support that a Mediterranean-style diet is able to prevent cardiovascular 
disease. However, the rationale of the PREDIMED trial is that there are no available 
randomized trials of primary prevention and this evidence is based only in observational 
studies of MD and cardiovascular disease [25-27]. Furthermore, in the meta-analysis by 
Sofi et al. [27] most observational information came from studies conducted in non-
Mediterranean countries. The single available trial of MD in cardiovascular prevention 
[28] was a secondary prevention trial (i.e., all participants had had a previous 
myocardial infarction before entering the trial) and it has been criticized because of 
methodological limitations [17]. The PREDIMED trial was launched to overcome these 
limitations and to provide the best possible evidence to support the hypothesis that a 
MD can prevent heart disease. The design of the PREDIMED trial has been reported in 
detail elsewhere [19, 29]. Briefly, the PREDIMED trial is a large, parallel-group, 
multicenter, randomized, and controlled clinical trial that aims to assess the effects of a 
Mediterranean-type diet on CVD. Eligible participants were community-dwelling men, 
55 to 80 years of age, and women, 60 to 80 years of age, who fulfilled at least 1 out of 2 
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criteria: type 2 diabetes or 3 or more CVD risk factors [19]. Type 2 diabetes mellitus 
was defined according to the American Diabetic Association criteria. The duration of 
diabetes at enrollment was higher than 5 years for 49% of diabetics included, 38% had 
the diagnosis between 1 and 5 years, and only 13% were diagnosed in the previous year. 
As much as 13% of diabetics included in the trial in our center were treated with insulin 
and 54% were using oral antidiabetic agents.  
Participants are assigned to one of three different dietary patterns (low-fat diet, 
Mediterranean diet (MD) supplemented with nuts [MD+nuts], and Mediterranean diet 
supplemented with virgin olive oil [MD+VOO]) [19].  
In the current analysis, data from one of the center of this trial were analyzed as an 
observational cohort study because the genetic analysis was not a part of the 
interventional project. In the present analyses we included data from 774 participants 
enrolled in the AP-UNAV recruitment center in Pamplona, in which the retention rate 
during the third year was greater than 80 %. As much as 137 subjects were excluded 
from the trial because we did not obtain DNA samples from them or because their 
adiposity measures were not recorded. All participants provided informed consent and 
the protocol was approved by the institutional review boards of the participating centre 
according to the Declaration of Helsinki. 
Dietary assessment 
The dietary habits of participants, both at baseline and after follow-up for 36 months, 
were assessed using a semi-quantitative 137-item FFQ previously validated in Spain 
[30]. Furthermore, details about the dietary assessment are described elsewhere [19].  
After the screening visit, and based on a baseline short (14-item) questionnaire  
specifically targeted to assess adherence to the Mediterranean diet [21, 29, 31], each 
participant was given personalized dietary advice by the dietician during a 30-min 
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session. Participants allocated to a low-fat diet were advised to reduce all types of fat 
and were given written recommendations according to American Heart Association 
guidelines [32]. The intensity of the intervention in the two MD groups was higher than 
in the control group [29].  The MD participants received instructions directed to upscale 
the MD 14-item score, including (1) the use of olive oil for cooking and dressing; (2) 
increased consumption of vegetables, nuts, and fish products; (3) consumption of white 
meat instead of red or processed meat; (4) preparation of homemade sauce by 
simmering tomato, garlic, onion, and aromatic herbs with olive oil to dress vegetables, 
pasta, rice, and other dishes; and (5) for alcohol drinkers, to follow a moderate pattern 
of red wine consumption. No energy restrictions were suggested for the MD groups. 
Participants in the MD groups were given free VOO (15 L for 3 months) or sachets of 
walnuts, hazelnuts, and almonds (1,350 g of walnuts [15 g/d], 675 g of hazelnuts [7.5 
g/d], and 675 g of almonds [7.5 g/d], for 3 months). To improve compliance and 
account for family needs, participants in the corresponding MD groups were given 
excess VOO or additional packs of nuts. One week after a participant's inclusion, 1-h 
group session (up to 20 participants) for each MD group, was held by the dietician. 
Each session consisted of an informative talk and written material with elaborated 
descriptions of typical Mediterranean foods, seasonal shopping lists, meal plans, and 
recipes. All participants had free and continuous access to their dietician throughout the 
study [29, 33, 34]. 
Genotyping 
Overnight fasting venous blood samples were collected in EDTA added tubes. DNA 
was extracted from the buffy coat fraction using a commercial kit (Master PureTM; 
Epicentre, Madison, WI, USA). All the subjects were genotyped for the -4034 A/C (rs 
822395), +45 T/G (rs 2241766), +276 G/T (rs 1501299) SNPs of the adiponectin gene 
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using Taqman real time PCR followed by an allelic discrimination by means of an ABI 
PRISM 7000. The probes and the primers for this assay were designed by Applied 
Biosystems (Madrid, Spain). Replicate quality control samples were included in every 
genotyping plate with more than 99% of concordance. 
Statistical analysis 
A χ2 test was used to evaluate the Hardy-Weinberg equilibrium. The Kolmogorov-
Smirnov test was used to determine variable distribution. Descriptive analyses of 
variables between the three interventional groups were performed using parametric tests 
(Student’s t-tests, ANOVA followed by Bonferroni post hoc tests).  
Regarding the statistical power, assuming a two-tailed alpha error of 0.05 and two 
groups of 196 and 302 subjects, we would be able to detect a difference in body weight 
changes ≥1 kg, with a statistical power of 80%.  
The effects of the adiponectin gene variants on body weight changes were evaluated 
with multivariate linear regression models adjusting for relevant variables: age, sex, 
baseline BMI, and diabetes. Baseline leisure time physical activity was initially 
included in the model, but did not have any significant effect so that it was removed. 
To analyze potential interactions between the nutritional intervention and the 
polymorphisms, the interaction product-term (MD x [polymorphism model]) was 
included in each regression model. F partial tests were performed to assess the statistical 
significance of the interaction product-terms were included. 
 
RESULTS 
Prevalence of overweight and obesity in the study population was 51% and 38%, 
respectively. Baseline characteristics of the participants according to the allocation to 
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the three nutritional groups are shown in Table 1. As expected, no statistically 
significant differences were found among the three groups.  
We observed that the distribution of macronutrient intake was significantly different 
among the three groups after 3 years of intervention (Table 2). The control group had 
the highest protein and carbohydrate intake, whereas MD subjects had the highest intake 
of mono and polyunsaturated fat but not of saturated fat. Moreover, we confirmed that 
the highest intake of virgin olive oil was present in the MD+VOO group (p<0.001), and 
that the nuts group had also significantly higher intake of virgin olive oil than the 
control group (p=0.008). Likewise, the highest intake of nuts was observed in the 
MD+nuts group (p<0.001), having the MD+VOO group significantly higher intake of 
nuts compared to the control group (p=0.001). 
The genotype distribution for the three studied polymorphisms did not deviate from 
Hardy-Weinberg equilibrium. The genotype frequencies for the adiponectin 
polymorphisms were: for the -4034A/C SNP: AA 43%, AC 47% and CC 10%; for the 
+45T/G SNP: TT 63%, TG 32%, and GG 5%; for the +276G/T SNP: GG 52%, GT 
41%, and TT 7%. Table 3 shows the baseline characteristics according to the studied 
polymorphisms: -4034A/C, +45T/G, and +276G/T of the adiponectin gene. GG subjects 
for the +45T/G gene variant presented higher systolic blood pressure at the beginning of 
the study (p=0.004). The other studied variables were similar among the genotypes for 
the different polymorphisms. 
To analyze the effects of the nutritional intervention and the polymorphism on 3-year 
body weight changes, we first investigated the influence of the intervention. Mean body 
weight changes in the three groups were similar: 0.04±3.9 kg, -0.17±4.2 kg and 
0.03±3.8 kg in the control, MD+VOO and MD+Nuts groups, respectively. The analysis 
regarding the three adiponectin gene variants was performed. The -4034A/C appeared to 
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follow a dominant model when mean body weight changes were analyzed: for AA 
subjects: 0.05±3.8 kg and for AT+TT subjects: -0.12±4.2 kg. The +45T/G and +276G/T 
polymorphisms of the adiponectin gene seem to follow a recessive model being body 
weight changes for the +45T/G: TT+TG subjects: -0.11±4.0 kg and GG subjects: 
1.13±4.3 kg; and for the +276G/T: GG+GT subjects: -0.10±4.0 kg and TT subjects 
0.83±4.2 kg. Although there were no statistically significant differences, both recessive 
models appeared to be associated with higher body weight gain. 
To better characterize the effects of the three polymorphisms and the nutritional 
intervention on 3-year body weight changes, multiple linear regression models adjusted 
for age, sex, diabetes status, baseline BMI were fitted. The first model considered the 
dominant model for the -4034A/C polymorphism. Neither the polymorphism nor the 
intervention presented a significant effect on body weight changes (data not shown). 
The second regression model included the recessive model of the +45T/G adiponectin 
gene variant (Table 4). GG subjects had the highest body weight gain (B=1.399; 
B=0.043). The nutritional intervention, per se, had no significant effect. When in a third 
regression model the +276G/T polymorphism was included as the recessive model, the 
TT subjects presented a tendency to have higher body weight gain (B=1.033; p=0.079). 
This effect was statistically significant among men (B=0.038; p=0.038) having TT 
subjects the highest 3-year body weight gain (data not shown). A study merging both 
recessive models together (+45T/G and + 276G/T) is not possible due to the low 
frequency of homozygous subjects for the mutations.  
To analyze the combined effects of the polymorphisms, multiple regression models 
were adjusted for age, sex, diabetes and baseline BMI. Each model considered the 
intervention, control versus MD (MD+VOO and MD+Nuts merged together), the 
studied polymorphism, and the interaction product-term between the intervention 
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(Control vs. MD) and the polymorphism. The first included the dominant model for the 
-4034 A/C adiponectin gene variant, and the interaction product-term (AA vs. AC+CC) 
x intervention. No significant result was observed (data not shown).  The second model 
included the +45T/G as the recessive model and the interaction product-term (TT+TG 
vs. GG) x intervention. The interaction was not statistically significant (data not shown). 
The third model included the recessive model of the +276G/T and the interaction 
(GG+GT vs. TT) x intervention. The interaction was marginally significant (B= -2.381; 
p=0.053) showing that TT subjects allocated to a MD diet group appeared to have a 
reduction in body weight gain (Table 5). The F partial test revealed that the model 
tended to improve when the interaction product-term was included in the model (F= 
3.74; p=0.053). 
Moreover, in every regression model, we observed that the baseline BMI (p<0.001) was 
inversely associated body weight gain. Meanwhile, the presence of diabetes was linked 
to a lower 3-year body weight gain in this intervention study (p<0.05). 
DISCUSSION 
Our data suggest an implication of adiponectin gene variants (+45T/G and +276G/T) in 
body weight changes after three years of nutritional intervention. Moreover, a potential 
interaction between the TT genotype of the +276T/G SNP and the MD+VOO was 
found.  
This study analyzes the combined effects of a nutritional intervention with a 
Mediterranean diet and genetic variation in adiponectin gene on 3-year body weight 
changes. On one hand, our results proved the effectiveness of the Mediterranean diet 
intervention since the fat intake distribution in the three nutritional groups changed in 
the expected direction [29, 31]. We observed that the MD did not lead to a higher 3-year 
body weight change. Furthermore, it seemed that both MD, but specially the diet rich in 
 10
virgin olive oil, tended to lead to a lower body weight gain. The finding that the MD 
adherence did not lead to a higher BMI was previously reported [35].  
On the other hand, we analyzed three adiponectin gene variants: -4034A/C, +45T/G, 
and +276G/T. The first SNP is located in the promoter region of the gene and we did 
not find any effect on body weight changes. There are few studies analyzing this 
polymorphism and no association with serum adiponectin levels [36] but a slight 
relationship with diabetes risk [37] was reported. We observed that the +45T/G (located 
in exon 2) was associated with body weight change, having GG subjects greater 3-year 
body weight gain independently of the nutritional group. The G-allele was previously 
reported to be associated with obesity, usually linked to diabetes [11, 38]. Regarding to 
the +276G/T polymorphism, located in the second intron of the gene, we observed a 
tendency within TT subjects to have higher body weight gain than subjects with the 
other genotypes. This tendency was statistically significant in men showing that TT 
subjects had higher 3-year body weight gain. It was found that T-allele of the +276G/T 
polymorphism was associated with higher body fat in Swedish population [39] and with 
severe obesity in a French Caucasian population [40].  
In our study, a potential interaction between the MD (VOO+Nuts) intervention and 
+276TT genotype in the whole population was found, showing that TT subjects 
allocated to MD had lower body weight gain. Thus, it appeared that although the TT 
genotype was predicted to have higher body weight gain, this effect was attenuated 
when these subjects followed a Mediterranean-style diet. Although there are studies 
analyzing the effects of interactions between dietary components and this 
polymorphism on serum adiponectin levels [41], there are no reports assessing the 
interaction between the Mediterranean diet and adiponectin gene variants on adiposity. 
It has been shown that the MD was able to reduce the risk of obesity [42] and metabolic 
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syndrome [43]. There are studies showing that a greater adherence to MD is associated 
with increased adiponectin levels in diabetic [44] and healthy women [45]. We 
hypothesized that the +276T/G adiponectin gene variant may be interacting in this 
association and consequently modifying body weight regulation. In a previous study, 
Goyenechea et al. [14] suggested an association between an energy restricted dietary 
intervention and a promoter polymorphism (-11391 G/A) of the adiponectin gene 
protecting against weight gain. 
In this substudy, we previously found that MD diet may be modifying the effects of 
other gene variants and body weight changes, such as Pro12Ala polymorphism of 
PPARG gene or rs9939609 T/A of FTO gene [31, 46]. Moreover, in the literature we 
found interactions between SNPs and other lifestyle changes, such as FTO rs9939609 
and physical activity on BMI [47]. 
Moreover, we observed that the highest the baseline BMI the lowest was body weight 
gain after 3 years of intervention. This result agrees with previous findings that showed 
a positive and independent relationship between weight loss and pre-treatment body 
weight [48, 49].  
A potential drawback of the design of our study is that a real control group (not 
Mediterranean, not low fat) that would possibly show a body weight increase associated 
with the gene variants is missing. We acknowledge this limitation that should be taken 
into account for the interpretation of our findings. However, the intensity of the 
nutritional intervention in the low-fat diet group was lower than in the two MD groups. 
Moreover, the absolute magnitude of the achieved reduction in total fat intake in the 
low-fat group was not impressive [29]. Therefore, the low-fat group was in fact playing 
the role of a control group.  
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Our data reinforce the idea that MD-style diet by lowering the risk of 
overweight/obesity may reduce obesity comorbidities. Moreover, the study of 
interactions between MD and adiponectin gene variants interactions will provide 
evidence in the field of personalized nutrition. 
In conclusion, adiponectin gene variation appeared to be associated with 3-year body 
weight changes in a high cardiovascular risk population. This association may be 
modulated by a nutritional intervention with a Mediterranean-style diet. 
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TABLES 
 
Table 1 Baseline and 3-year characteristics of the participants according to the nutritional group 
 
 
 
 
 
 CONTROL 
(n=196) 
VIRGIN OLIVE 
OIL (n=302) 
TREE NUTS  
(n=239) 
Sex (%Female) 57 56 52 
Age (years) 68.3±6.0 67.7±6.7 67.6±6.7 
Waist/Height  0.6±0.1 0.6±0.1 0.6±0.1 
 
Baseline 
94.9±11.0 96.0±10.4 95.1±9.6 
Waist  
circumference (cm) 
3-year 95.1±10.9 96.3±10.0 95.0±9.5 
 
Baseline 
74.5±11.8 75.6±11.9 74.6±10.3 
Weight (kg) 
3-year 74.4±12.4 75.6±11.8 74.6±10.4 
 
Baseline 
29.2±3.5 29.2±3.3 29.1±3.1 
BMI (kg/m²) 
3-year 29.1±3.5 29.2±3.3 29.1±3.2 
Systolic blood pressure (mm Hg) 155.4±21.3 154.7±21.0 155.1±21.1 
Diastolic blood pressure (mm Hg) 86.4±10.5 85.8±10.6 87.1±10.6 
Diabetes (%) 68 64 63 
Smoking habit (%Current Smokers) 18 16 13 
3-year body weight changes (kg) 0.04±3.9 -0.17±4.2 0.02±3.8 
Table 2. Distribution of macronutrients and Mediterranean diet specific nutrients after 3 years of nutritional intervention according to the 
nutritional group 
 
P Values for the between groups  differences  
CONTROL       
(n=196)1
MD+VIRGIN OLIVE 
OIL (n=302)1
MD+TREE NUTS  
(n=239)1
TMD+VOO 
versus CONTROL
TMD+NUTS 
versus 
CONTROL 
TMD+NUTS 
versus 
TMD+VOO 
Total energy intake 
(Kcal/day) 
2287.8±676.8 2532.8±551.1 2574.0±595.3 <0.001 <0.001 1.000 
Carbohydrates (%Total 
energy intake) 
43.9±6.8 39.2±5.6 38.6±5.8 <0.001 <0.001 0.772 
Proteins (%Total energy 
intake) 
16.4±2.9 15.3±2.2 15.4±2.0 <0.001 <0.001 1.000 
Total fat (%Total energy 
intake) 
37.2±6.2 42.5±5.3 42.8±5.4 <0.001 <0.001 1.000 
Saturated fat (%Total 
energy intake) 
9.0±2.1 9.2±1.6 9.3±1.6 0.756 0.281 1.000 
MUFA (%Total energy 
intake) 
19.1±4.1 23.1±3.4 22.8±3.7 <0.001 <0.001 1.000 
PUFA (%Total energy 
intake) 
5.6±1.9 6.7±1.5 7.3±1.3 <0.001 <0.001 <0.001 
Virgin olive oil (10g) 
(servings/day) 
3.0±2.4 6.3±1.1 4.5±2.8 <0.001 <0.001 <0.001 
Nuts (25g) (servings/day) 2.5±5.2 6.1±8.2 13.4±6.5 <0.001 <0.001 <0.001 
1Mean±standar deviation  
MUFA: monounsaturated fatty acid; PUFA: polyunsaturated fatty acid; TMD: traditional Mediterranean diet; VOO: virgin olive oil.
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Table 3 Baseline and 3-year characteristics of the participants according to the genetic variants of the adiponectin gene 
 
-4034 A/C (rs 822395) +45 T/G (rs 2241766) +276 G/T (rs 1501299) a
 
AA 
(n=316) 
AC+CC 
(n=421) 
TT+TG 
(n=702) 
GG GG+GT 
(n=685) 
TT 
(n=50) (n=35) 
Sex (%Female) 55 56 55 60 54 64 
Age (years) 68.0±6.2 67.7±6.7 67.8±6.6 68.1±5.6 67.8±6.6 67.5±6.1 
Waist/Height  0.6±0.1 0.6±0.1 0.6±1 0.6±0.1 0.6±0.1 0.6±0.1 
Baseline 95.2±10.5 95.5±10.2 95.4±10.4 95.4±9.3 95.4±10.2 94.9±11.3 Waist 
circumference (cm) 3-year 95.5±10.6 95.6±9.7 95.5±10.1 97.3±9.4 95.5±10.0 95.9±11.0 
Baseline 75.3±11.5 74.7±11.3 75.0±11.4 75.3±10.9 75.1±11.3 74.5±11.9 
Weight (kg) 
3-year 75.3±12.0 74.7±11.1 74.8±11.5 76.7±12.2 75.0±11.4 75.3±13.2 
Baseline 29.1±3.1 29.2±3.3 29.1±3.3 29.6±2.9 29.2±3.3 29.2±2.9 
BMI (kg/m²) 
3-year 29.1±3.3 29.2±3.3 29.1±3.3 30.1±3.4 29.1±3.3 29.6±3.0 
Systolic blood pressure (mm Hg) 156.3±20.5 154.1±21.5 154.6±20.9 165.2±22.6 b 155.1±21.1 154.0±22.0 
Diastolic blood pressure (mm Hg) 87.0±11.0 86.0±11.0 86.3±10.6 89.0±11.0 86.1±0.6 86.5±11.1 
Diabetes (%) 32 37 35 26 35 34 
Smoking habit (%Current Smokers) 16 15 16 17 16 14 
3-year body weight change (kg) 0.05±3.82 -0.12±4.17 -0.11±4.01 1.13±4.33 -0.10±4.00 
 
0.83±4.20 
a Two subjects were not included because of missing data for this analysis  
b The differences between TT+TG and GG subjects were statistically significant (p=0.004) 
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Table 4. Multiple regression model assessing the effects of the +45 T/G (rs 2241766) polymorphism of the adiponectin gene on body weight 
changes after three years of a nutritional intervention  
 
 
 
 
 
 
 
 
 
 
a  3-year body weight change (3-year body weight-baseline body weight) 
 
 
 
 B (95% CI)  a p value 
Age -0.028 (-0.074 to 0.018) 0.235 
Males 0 (ref.)  Sex  
Females -0.369 (-0.973 to 0.234) 0.230 
Baseline BMI -0.276 (-0.365 to -0.187) <0.001 
No 0 (ref.)  Diabetes 
Yes -0.618 (-1.228 to -0.009) 0.047 
Control 0 (ref.)  
MD+VOO -0.141 (-0.865 to 0.584) 0.703 
Nutritional intervention 
MD+Nuts 0.005 (-0.756 to 0.766) 0.989 
TT+TG 0 (ref.)  +45 T/G polymorphism 
(recessive model) 
GG 1.399 (0.045 to 2.754) 0.043 
 
Table 5. Multiple regression model assessing the effects of the interaction between the 
+276 G/T polymorphism (recessive model) of adiponectin gene and the nutritional 
intervention on 3-year body weight changes  
 
 B (95% CI) a p value 
Age -0.027 (-0.074 to 0.019) 0.242 
Males 0 (ref.) Sex  
Females -0.374 (-0.977 to 0.229) 
 
0.223 
Baseline BMI -0.274 (-0.363 to -0.186) <0.001 
No 0 (ref.) Diabetes 
Yes -0.637 (-1.246 to -0.029) 
 
0.040 
Control 0 (ref.) Nutritional intervention 
MD 0.193 (-0.496 to 0.882) 
 
0.583 
GG+GT 0 (ref.) +276 G/T polymorphism 
TT 2.586 (0.632 to 4.540) 
 
0.010 
Control x TT 0 (ref.) Nutritional intervention 
x polymorphism 
MDb x TT -2.381 (-4.798 to 0.035) 
 
0.053 
 
a  3-year body weight change (3-year body weight-baseline body weight) 
b MD refers to MD+VOO and MD+Nuts merged together 
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